Jun 29, 2023 / 01:00AM GMT
Jane Lowe - IR Department - Investor Relations. Board Advisor
Well, hello, everyone, and thank you for joining us for Inoviq special investor briefing regarding the excellent clinical data for SubB2M/CA15-3 breast cancer test as announced this week. My name is Jane Lowe, and I'll be your host for today's session. For those new to Inoviq, the company is developing Next-generation Exosome Solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. It has a number of new tests coming through the pipeline, including the focus of today's briefing, which is SubB2M/CA15-3 breast cancer test.
So, our format for today will be that CEO, Leearne Hinch, Dr. Leearne Hinch and CSO Professor. Greg Rice will deliver a presentation and that presentation was lodged with the ASX this morning. They will speak for about 20 minutes or so and after that, we'll open up the floor to Q&A for about 15 minutes.
Through the Q and A session, Leearne and Greg will be joined by Inoviq's CFO and Company Secretary Mark Edwards. And this is designed to be quite an
INOVIQ Ltd Investor Briefing Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot